美国报告的与 COVID-19 和镰状细胞病相关的死亡病例。
COVID-19 and Sickle Cell Disease-Related Deaths Reported in the United States.
机构信息
Division of Blood Disorders, National Center on Birth Defects and Developmental Disabilities, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Division of Pediatric Hematology/Oncology, University of Illinois at Chicago, Chicago, IL, USA.
出版信息
Public Health Rep. 2022 Mar-Apr;137(2):234-238. doi: 10.1177/00333549211063518. Epub 2022 Jan 21.
Sickle cell disease (SCD) is associated with increased risk of poor health outcomes from respiratory infections, including COVID-19 illness. We used US death data to investigate changes in SCD-related mortality before and during the COVID-19 pandemic. We estimated annual age- and quarter-adjusted SCD-related mortality rates for 2014-2020. We estimated the number of excess deaths in 2020 compared with 2019 using the standardized mortality ratio (SMR). We found 1023 SCD-related deaths reported in the United States during 2020, of which 86 (8.4%) were associated with COVID-19. SCD-related deaths, both associated and not associated with COVID-19, occurred most frequently among adults aged 25-59 years. The SCD-related mortality rate changed <5% year to year from 2014 to 2019 but increased 12% in 2020; the sharpest increase was among adults aged ≥60 years. The SMR comparing 2020 with 2019 was 1.12 (95% CI, 1.06-1.19). Overall, 113 (95% CI, 54-166) excess SCD-related deaths occurred in 2020.
镰状细胞病（SCD）与呼吸道感染不良健康结局风险增加相关，包括 COVID-19 疾病。我们使用美国死亡数据调查了 COVID-19 大流行前后 SCD 相关死亡率的变化。我们估计了 2014-2020 年的年度年龄和季度调整的 SCD 相关死亡率。我们使用标准化死亡率比（SMR）估计了 2020 年与 2019 年相比的超额死亡人数。我们发现，2020 年美国报告了 1023 例与 SCD 相关的死亡，其中 86 例（8.4%）与 COVID-19 相关。与 COVID-19 相关和不相关的 SCD 相关死亡最常发生在 25-59 岁的成年人中。2014 年至 2019 年，SCD 相关死亡率每年变化<5%，但 2020 年增加了 12%；增长率最高的是年龄≥60 岁的成年人。与 2019 年相比，2020 年的 SMR 为 1.12（95%CI，1.06-1.19）。总体而言，2020 年有 113 例（95%CI，54-166）与 SCD 相关的死亡人数过多。
Zotero 插件